COVID-19: Thromboserisiko und Antikoagulationsmanagement

Bereits früh im Verlauf der COVID-19-Pandemie wurde eine Häufung von Thromboembolien bei schwer an COVID-19 erkrankten Patienten beobachtet. In frühen Berichten über Patienten aus Wuhan und aus New York wurde ein Zusammenhang zwischen erhöhten D-Dimeren und der Wahrscheinlichkeit, an der Erkrankung zu versterben, beobachtet.

Kernaussagen

• COVID-19 wird durch eine Infektion mit SARS-CoV-2 ausgelöst und kann unterschiedlich schwer verlaufen.

• Die Erkrankung geht mit einem erhöhten Risiko für Thromboembolien, aber auch für Blutungen einher.

• Die Diagnose und die Therapie von schweren Thromboembolien unterscheidet sich bei COVID-19 nicht von anderen Krankheitsbildern.

• Patienten, die stationär behandelt werden, sollten in der Regel eine medikamentöse Thromboembolieprophylaxe erhalten.

• Eine therapeutische Antikoagulation ist nur in Ausnahmefällen und bei spezifischer Indikation (z. B. Lungenembolie oder Vorhofflimmern) indiziert.

Schlüsselwörter

COVID-19 - Thromboembolieprophylaxe - Antikoagulation - Lungenembolie

Publication History

Article published online:
06 December 2022

• Literatur

• 1 Iba T, Levy JH, Levi M. et al. Coagulopathy of Coronavirus Disease 2019. Crit Care Med 2020; 48: 1358-1364 DOI: 10.1097/CCM.0000000000004458. (PMID: 32467443)
• 2 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062 DOI: 10.1016/S0140-6736(20)30566-3. (PMID: 32171076)
• 3 Cummings MJ, Baldwin MR, Abrams D. et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763-1770 DOI: 10.1016/S0140-6736(20)31189-2. (PMID: 32442528)
• 4 Ackermann M, Verleden SE, Kuehnel M. et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med 2020; 383: 120-128 DOI: 10.1056/NEJMoa2015432. (PMID: 32437596)
• 5 Pons S, Fodil S, Azoulay E. et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care 2020; 24: 353 DOI: 10.1186/s13054-020-03062-7. (PMID: 32546188)
• 6 Varga Z, Flammer AJ, Steiger P. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395: 1417-1418 DOI: 10.1016/S0140-6736(20)30937-5. (PMID: 32325026)
• 7 Jimenez D, Garcia-Sanchez A, Rali P. et al. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021; 159: 1182-1196 DOI: 10.1016/j.chest.2020.11.005. (PMID: 33217420)
• 8 Wichmann D, Sperhake JP, Lutgehetmann M. et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020; 173: 268-277 DOI: 10.7326/M20-2003. (PMID: 32374815)
• 9 Bemtgen X, Zotzmann V, Benk C. et al. Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19. J Thromb Thrombolysis 2021; 51: 301-307 DOI: 10.1007/s11239-020-02217-1. (PMID: 32653986)
• 10 Doyle AJ, Hunt BJ, Sanderson B. et al. A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation. Crit Care Med 2021; 49: e663-e672 DOI: 10.1097/CCM.0000000000004971. (PMID: 33861545)
• 11 Seeliger B, Doebler M, Hofmaenner DA. et al. Intracranial Hemorrhages on Extracorporeal Membrane Oxygenation: Differences Between COVID-19 and Other Viral Acute Respiratory Distress Syndrome. Crit Care Med 2022; 50: e526-e538 DOI: 10.1097/CCM.0000000000005441. (PMID: 35020672)
• 12 Poissy J, Goutay J, Caplan M. et al. Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence. Circulation 2020; 142: 184-186 DOI: 10.1161/CIRCULATIONAHA.120.047430. (PMID: 32330083)
• 13 Lopes RD, de Barros ESPGM, Furtado RHM. et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021; 397: 2253-2263 DOI: 10.1016/S0140-6736(21)01203-4.
• 14 ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators. et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021; 385: 790-802 DOI: 10.1056/NEJMoa2105911. (PMID: 12743668)
• 15 Nopp S, Moik F, Jilma B. et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4: 1178-1191 DOI: 10.1002/rth2.12439. (PMID: 33043231)
• 16 Bilaloglu S, Aphinyanaphongs Y, Jones S. et al. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. JAMA 2020; 324: 799-801 DOI: 10.1001/jama.2020.13372. (PMID: 32702090)
• 17 Vincent JL, Levi M, Hunt BJ. Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia. Lancet Respir Med 2022; 10: 214-220 DOI: 10.1016/S2213-2600(21)00455-0. (PMID: 34838161)
• 18 Perico L, Benigni A, Casiraghi F. et al. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 2021; 17: 46-64 DOI: 10.1038/s41581-020-00357-4. (PMID: 33077917)
• 19 Bonaventura A, Vecchié A, Dagna L. et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 2021; 21: 319-329 DOI: 10.1038/s41577-021-00536-9. (PMID: 33824483)
• 20 Wagner DD, Heger LA. Thromboinflammation: From Atherosclerosis to COVID-19. Arterioscler Thromb Vasc Biol 2022; 42: 1103-1112 DOI: 10.1161/atvbaha.122.317162. (PMID: 35861953)
• 21 Osuchowski MF, Winkler MS, Skirecki T. et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 2021; 9: 622-642 DOI: 10.1016/S2213-2600(21)00218-6. (PMID: 33965003)
• 22 Remmelink M, De Mendonca R, D’Haene N. et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care 2020; 24: 495 DOI: 10.1186/s13054-020-03218-5. (PMID: 32787909)
• 23 Del Valle DM, Kim-Schulze S, Huang HH. et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26: 1636-1643 DOI: 10.1038/s41591-020-1051-9. (PMID: 32839624)
• 24 Ward SE, Fogarty H, Karampini E. et al. ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost 2021; 19: 1914-1921 DOI: 10.1111/jth.15409. (PMID: 34053187)
• 25 Zuo Y, Warnock M, Harbaugh A. et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep 2021; 11: 1580 DOI: 10.1038/s41598-020-80010-z. (PMID: 33452298)
• 26 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; 383: 2451-2460 DOI: 10.1056/NEJMcp2009575. (PMID: 32412710)
• 27 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506 DOI: 10.1016/S0140-6736(20)30183-5. (PMID: 31986264)
• 28 Vincent JL. COVID-19: it’s all about sepsis. Future Microbiol 2021; 16: 131-133 DOI: 10.2217/fmb-2020-0312. (PMID: 33491491)
• 29 Gurbel PA, Tantry US, Storey RF. International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. J Thromb Thrombolysis 2021; 52: 992-998 DOI: 10.1007/s11239-021-02465-9. (PMID: 34021852)
• 30 Barrett TJ, Lee AH, Xia Y. et al. Platelet and Vascular Biomarkers Associate With Thrombosis and Death in Coronavirus Disease. Circ Res 2020; 127: 945-947 DOI: 10.1161/CIRCRESAHA.120.317803. (PMID: 32757722)
• 31 Leentjens J, van Haaps TF, Wessels PF. et al. COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol 2021; 8: e524-e533 DOI: 10.1016/S2352-3026(21)00105-8. (PMID: 33930350)
• 32 Konstantinides SV, Meyer G, Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603 DOI: 10.1093/eurheartj/ehz405. (PMID: 31504429)
• 33 Connors JM, Brooks MM, Sciurba FC. et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 2021; 326: 1703-1712 DOI: 10.1001/jama.2021.17272. (PMID: 34633405)
• 34 Ananworanich J, Mogg R, Dunne MW. et al. Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19. Clin Infect Dis 2022; 75: e473-e481 DOI: 10.1093/cid/ciab813. (PMID: 34523673)
• 35 Spyropoulos AC, Goldin M, Giannis D. et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 2021; 181: 1612-1620 DOI: 10.1001/jamainternmed.2021.6203. (PMID: 34617959)
• 36 Sholzberg M, Tang GH, Rahhal H. et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021; 375: n2400 DOI: 10.1136/bmj.n2400. (PMID: 34649864)
• 37 Kluge S, Janssens U, Welte T. et al. S3-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19 (12.09.2022). AWMF-Register-Nr. 113/001. Accessed November 21, 2022 at: https://register.awmf.org/assets/guidelines/113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19_2022-09_1.pdf
• 38 REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators. et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021; 385: 777-789 DOI: 10.1056/NEJMoa2103417. (PMID: 34251506)
• 39 Sadeghipour P, Talasaz AH. INSPIRATION Investigators. et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021; 325: 1620-1630 DOI: 10.1001/jama.2021.4152. (PMID: 33734299)
• 40 Perepu US, Chambers I, Wahab A. et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021; 19: 2225-2234 DOI: 10.1111/jth.15450. (PMID: 34236768)
• 41 Ramacciotti E, Barile Agati L, Calderaro D. et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022; 399: 50-59 DOI: 10.1016/S0140-6736(21)02392-8.